A Multi-centre, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of SB-649868 (10, 30 mg and 60 mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia.
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2012
At a glance
- Drugs GSK 649868 (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Aug 2012 Actual end date (1 May 2007) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Results published in the Sleep.
- 21 Aug 2007 Status changed from recruiting to completed.